HEPATOPROTECTIVE EFFECTS OF NGM282 COMPARED TO OBETICHOLIC ACID AND BEZAFIBRATE IN MOUSE MODELS OF CHOLESTASIS

被引：3
|
作者：
Luo, J. [1 ]
Ko, B. [1 ]
To, C. [1 ]
Lindhout, D. [1 ]
Ling, L. [1 ]
Chen, J. L. [1 ]
Parsons, T. [1 ]
Rossi, S. [1 ]
DePaoli, A. [1 ]
Tian, H. [1 ]
机构：
[1] NGM Biopharmaceut Inc, San Francisco, CA USA
来源：
JOURNAL OF HEPATOLOGY | 2014年 / 60卷 / 01期
关键词：
D O I：
10.1016/S0168-8278(14)61475-6
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1308
引用
收藏
页码：S531 / S531
页数：1
相关论文
共 50 条
  • [1] NGM282 DEMONSTRATES POTENT ANTIFIBROTIC ACTIVITY IN A MOUSE MODEL OF SEVERE CHOLESTATIC FIBROSIS
    Luo, J.
    Ko, B.
    To, C.
    Ling, L.
    Rossi, S.
    DePaoli, A.
    Tian, H.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S779 - S779
  • [2] Bezafibrate improves the effect of obeticholic acid on cholestasis in patients with primary biliary cholangitis
    Smets, Lena
    Liliane, Schrijvers
    Hannelie, Korf
    Schalk, Van der Merwe
    Frederik, Nevens
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E130 - E130
  • [3] Obeticholic acid but not bezafibrate treatment improves cholestasis-induced cognitive decline
    Gee, Lucy
    Burgoyne, Rachel
    Lebeau, Fiona
    Jones, David
    Oakley, Fiona
    JOURNAL OF HEPATOLOGY, 2020, 73 : S198 - S198
  • [4] TREATMENT WITH NGM282 SIGNIFICANTLY IMPROVES LIVER HISTOPATHOLOGY IN A MOUSE MODEL OF NON-ALCOHOLIC STEATOHEPATITIS (NASH)
    Luo, J.
    Ko, B.
    To, C.
    Ling, L.
    Rossi, S.
    DePaoli, A.
    Tian, H.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S694 - S694
  • [5] NGM282 is a Potent Modulator of Bile Acid Synthesis in Humans via Suppression of CYP7A1 Activity
    Rossi, Stephen
    Elliott, Michael
    Setchell, Kenneth D.
    Nkinin, Stephenson W.
    Luo, Jian
    Ling, Lei
    Allamneni, Krishna P.
    Tian, Hui
    DePaoli, Alex M.
    HEPATOLOGY, 2014, 60 : 352A - 353A
  • [6] NGM282 Ameliorates Hepatic Lipotoxicity as Measured by Lipidomics and Gene Expression in a Diet-Induced Mouse Model of Nonalcoholic Steatohepatitis (NASH)
    Ling, Lei
    Zhou, Mei
    Learned, Marc
    Rossi, Stephen J.
    DePaoli, Alex M.
    Tian, Hui
    HEPATOLOGY, 2017, 66 : 1063A - 1063A
  • [7] Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial
    Oduyebo, Ibironke
    Camilleri, Michael
    Nelson, Alfred D.
    Khemani, Disha
    Nord, Sara Linker
    Busciglio, Irene
    Burton, Duane
    Rhoten, Deborah
    Ryks, Michael
    Carlson, Paula
    Donato, Leslie
    Lueke, Alan
    Kim, Kathline
    Rossi, Stephen J.
    Zinsmeister, Alan R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 (05): : 725 - 734
  • [8] Veillonella as a bile acid-sensitive bacteria and a microbiome-based biomarker for aldafermin (NGM282) in patients with non-alcoholic steatohepatitis
    Loomba, Rohit
    Ling, Lei
    Dinh, Duy
    Baxter, Bryan
    DePaoli, Alex
    Lieu, Hsiao
    Harrison, Stephen
    Sanyal, Arun
    JOURNAL OF HEPATOLOGY, 2020, 73 : S240 - S241
  • [9] Anti-inflammatory and Antifibrotic Activity of NGM282, A Novel Variant of FGF19, in an Mdr2-Deficient Mouse Model of Primary Sclerosing Cholangitis
    Ling, Lei
    Zhou, Mei
    Yang, Hong
    Learned, Marc
    Rossi, Stephen
    DePaoli, Alex M.
    Tian, Hui
    HEPATOLOGY, 2015, 62 : 309A - 309A
  • [10] NGM282, A NOVEL SPECIFIC INHIBITOR OF CYP7A1-MEDIATED BILE ACID SYNTHESIS, IS SAFE AND WELL TOLERATED WITH PREDICTABLE PHARMACOKINETICS IN HEALTHY HUMAN SUBJECTS
    Rossi, S.
    Allamneni, K.
    Elliott, M.
    Byrnes-Blake, K.
    Luo, J.
    Ling, L.
    Tian, H.
    De Paoli, A.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S533 - S533
12345